S-1 with leucovorin for gastric cancer: how far can it go?
Mené au Japon sur 145 patients atteints d'un cancer avancé de l'estomac, cet essai multicentrique randomisé de phase II compare l'efficacité, du point de vue de la réponse globale, et la toxicité de 3 combinaisons de chimiothérapie, S-1-leucovorine, S-1-leucovorine-oxaliplatine et S-1-cisplatine, en traitement de première ligne
Fluoropyrimidine-platinum doublets, with or without a third active cytotoxic agent, taxane, or anthracycline, are acceptable standard chemotherapeutic treatments for patients with advanced gastric cancer worldwide. However, the docetaxel-fluorouracil-cisplatin combination is deemed too toxic for daily practice. Additionally, the use of epirubicin-fluoropyrimidine-cisplatin has recently been challenged by the negative results of the UK MRC OE05 trial, in which neoadjuvant 96-h infusion of fluorouracil plus cisplatin had similar clinical outcomes in patients with oesophageal adenocarcinoma compared with epirubicin-cisplatin-capecitabine followed by surgery.
The Lancet Oncology , commentaire, 2014